Betahistine
Brand names: Serc
Betahistine is an oral histamine analogue used to reduce the frequency and severity of vertigo attacks, and the associated tinnitus and hearing loss, in Ménière's disease.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It acts as a weak histamine H1-receptor agonist and H3-receptor antagonist; it is thought to improve microcirculation in the inner ear and modulate vestibular activity, although the precise mechanism is not fully established.
Prescribing in practice
- Use with caution in asthma and in active or previous peptic ulcer disease, as histaminergic effects may provoke symptoms.
- Use caution in phaeochromocytoma; it is generally well tolerated, with mild gastrointestinal upset and headache the commonest effects.
- Review the response over time and reconsider the diagnosis or treatment if vertigo is not controlled.
Monitoring
No specific laboratory monitoring is required; assess clinically by the frequency and severity of vertigo, tinnitus and hearing symptoms.
Counselling the patient
- Take it with food to reduce stomach upset.
- Report worsening wheeze if you have asthma, or indigestion or stomach pain.
Evidence & guidelines
Widely used to reduce the burden of Ménière's-related vertigo; benefit is supported by clinical use and guidance, though trial evidence is mixed.
Reference: British Society of Audiology (BSA) Ménière's Guidelines; NICE Evidence; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020